The global blockbuster oncology brands market is poised to
reach USD 62.80 billion by 2027, according to a new report by Grand View
Research, Inc., progressing at a CAGR of 7.3% during the forecast period. Shift
towards immunotherapies coupled with increasing number of indication expansion
trials is one of the primary growth stimulants for the market.
Current market analysis reveals
Revlimid and Opdivo as bestselling therapies in the marketplace in 2017.
However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent
expiration will lower its revenue share in the market by 2027. Although
Keytruda poses strong competition to Opdivo, especially after bagging a
frontline approval for NSCLC in 2017, the immunotherapeutic is expected to
trail behind the latter by 2027.
Lifecycle management strategies,
including expansion of approved indications and development of combination
therapies, underline competitive dynamics in the global blockbuster oncology
brands market. Collaborative agreements signed by participating companies
facilitate development, commercialization, and regional expansion of products.
Such strategies not only enable players to gain easy access into new markets,
but also allow them to leverage scientific and technological expertise of their
collaborative partner.
Browse full research report on Blockbuster Oncology Brands Market: https://www.grandviewresearch.com/industry-analysis/blockbuster-oncology-brands-market
Further key findings from the report suggest:
- North America dominated the global arena in 2017, with
approximately 65.0% share. The region is likely to maintain its position
through 2027
- In terms of revenue, the lung cancer segment is estimated to
expand at a CAGR of over 9.0% during the forecast period
- The multiple myeloma segment held more than 30.0% of the
market revenue in 2017 and is anticipated to lose its position to lung
cancer by 2027
- Europe is projected to experience modest growth during the
forecast period due to delays in cost-effectiveness analysis, carried out
by health technology assessment bodies, slowing approval process and
lowering reimbursement
- Some of the key companies present in the market are Tesaro,
Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche
Ltd.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/blockbuster-oncology-brands-market/request/rs1
Grand View Research has segmented the global blockbuster oncology
brands market on the basis of brands, indication, and region:
Blockbuster Oncology Brands Outlook (Revenue, USD Million, 2015 -
2027)
- Opdivo
- Keytruda
- Perjeta
- Ibrance
- Tecentriq
- Gazyva
- Zejula
- Tagrisso
- Darzalex
- Imbruvica
- Revlimid
Blockbuster Oncology Brands Indication Outlook (Revenue, USD
Million, 2015 - 2027)
- Lung
cancer
- Breast
cancer
- Multiple
myeloma
- Lymphoma
- Others
Blockbuster Oncology Brands Regional Outlook (Revenue, USD
Million, 2015 - 2027)
- North
America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Italy
- Spain
- France
- Switzerland
- Poland
- Denmark
- Asia
Pacific
- China
- Japan
- India
- Australia
- New
Zealand
- Philippines
- Indonesia
- Hong
Kong
- Singapore
- South
Korea
- Latin
America
- Mexico
- Brazil
- Argentina
- Middle
East & Africa
- Saudi
Arabia
- Israel
- Turkey
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For
more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment